Champions Oncology Inc
F:2I3

Watchlist Manager
Champions Oncology Inc Logo
Champions Oncology Inc
F:2I3
Watchlist
Price: 5.15 EUR -4.63% Market Closed
Market Cap: 70m EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+94%
Revenue
Forecast
+18%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

2I3 Price Targets Summary
Champions Oncology Inc

Wall Street analysts forecast 2I3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 2I3 is 10.01 EUR with a low forecast of 9.91 EUR and a high forecast of 10.3 EUR.

2I3 Lowest Forecast
Wall Street Target
9.91 EUR
92% Upside
2I3 Average Forecast
Wall Street Target
10.01 EUR
94% Upside
2I3 Highest Forecast
Wall Street Target
10.3 EUR
100% Upside
Lowest
Price Target
9.91 EUR
92% Upside
Average
Price Target
10.01 EUR
94% Upside
Highest
Price Target
10.3 EUR
100% Upside
Champions Oncology Inc Competitors:
Price Targets
WAT
Waters Corp
30% Upside
LAB
Standard BioTools Inc
71% Upside
TKNO
Alpha Teknova Inc
118% Upside
T
TEM
Tempus AI Inc
12% Upside
WAT
Waters Corp
30% Upside
LAB
Standard BioTools Inc
71% Upside
TKNO
Alpha Teknova Inc
118% Upside
T
TEM
Tempus AI Inc
12% Upside
SHC
Sotera Health Co
23% Upside
CTKB
Cytek Biosciences Inc
56% Upside

Revenue
Forecast

Revenue Estimate
Champions Oncology Inc

For the last 8 years the compound annual growth rate for Champions Oncology Inc's revenue is 21%. The projected CAGR for the next 4 years is 18%.

21%
Past Growth
18%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Champions Oncology Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-32%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Champions Oncology Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-36%
Average Miss
What are analyst estimates?

See Also

Summary
2I3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
2I3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
2I3 stock valuation using valuation multiples.
Wall Street Estimates
2I3 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
2I3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 2I3's stock price target?
Price Target
10.01 EUR

According to Wall Street analysts, the average 1-year price target for 2I3 is 10.01 EUR with a low forecast of 9.91 EUR and a high forecast of 10.3 EUR.

What is Champions Oncology Inc's Revenue forecast?
Projected CAGR
18%

For the last 8 years the compound annual growth rate for Champions Oncology Inc's revenue is 21%. The projected CAGR for the next 4 years is 18%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 270,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.